default author photo

Kim Lee B. Sim

Sanaria Inc

SCHOLARLY PAPERS

3

DOWNLOADS

393

TOTAL CITATIONS

1

Scholarly Papers (3)

1.

Dose-Escalation, Double-Blind, Placebo-Controlled Evaluation of MAM01 Human Monoclonal Antibody for Protection Against Malaria: A First-in-Human, Phase 1 Adaptive Trial

Number of pages: 25 Posted: 23 Jun 2025
University of Maryland, Baltimore (UMB), - Center for Vaccine Development and Global Health, University of Maryland, Baltimore (UMB) - School of Medicine, affiliation not provided to SSRN, University of Maryland, Baltimore (UMB), University of Maryland, Baltimore (UMB), University of Maryland, Baltimore (UMB), Sanaria Inc, Sanaria Inc, Sanaria Inc, Sanaria Inc, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute, Gates Medical Research Institute and Gates Medical Research Institute
Downloads 201 (380,469)

Abstract:

Loading...

Malaria, Monoclonal antibody, Plasmodium falciparum, Circumsporozoite Protein, Repeat region, MAM01, Phase 1 trial, Subcutaneous, Intravenous

2.

Protection from Malaria after Pre-Conception PfSPZ Vaccine

Number of pages: 19 Posted: 10 Apr 2024
University of Sciences Techniques and Technologies of Bamako - Malaria Research & Training Center, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Columbia University, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, Government of the United States of America - Laboratory of Malaria Immunology and Vaccinology, Government of the United States of America - Frederick National Laboratory for Cancer Research, National Institutes of Health, NIAID/NIH - Laboratory of Malaria Immunology and Vaccinology, University of Sciences, Technique and Technologies of Bamako (USTTB), University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Center (MRTC), University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Sanaria Inc, Sanaria Inc, Sanaria Inc, Sanaria Inc, Sanaria Inc, Sanaria Inc, Sanaria Inc, Sanaria Inc, Sanaria Inc, University of Sciences, Technique and Technologies of Bamako (USTTB) - Malaria Research and Training Centre and NIAID/NIH - Laboratory of Malaria Immunology and Vaccinology
Downloads 132 (554,631)
Citation 1

Abstract:

Loading...

malaria, PfSPZ Vaccine, pre-conception, pregnancy

3.

Safety and Efficacy of Two Attenuated PfSPZ Vaccines in Malaria Inexperienced Soldiers Exposed to Plasmodium Falciparum Malaria Genetically Distant from the Vaccine Strain during Deployment to Papua Province, Indonesia

Number of pages: 43 Posted: 25 Feb 2026
Universitas Indonesia (UI), Sanaria Inc, Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI), Sanaria Inc, Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI), Sanaria Inc, Sanaria Inc, Sanaria Inc, Sanaria Inc, Sanaria Inc, Eijkman-Oxford Clinical Research Unit (EIMB), StatPlus Inc., StatPlus Inc., Government of the Republic of Indonesia, Muhammadiyah University, University of Maryland, University of Maryland, Sanaria Inc, Gatot Soebroto Army Hospital, Gatot Soebroto Army Hospital, Universitas Indonesia (UI), National Research and Innovation Agency (BRIN), Government of the Republic of Indonesia, Universitas Indonesia (UI), Universitas Indonesia (UI), Universitas Indonesia (UI) and Sanaria Inc
Downloads 60 (989,921)

Abstract:

Loading...

Plasmodium falciparum, PfSPZ Vaccine, PfSPZ-CVac, malaria vaccine, deployment, soldiers, vaccine efficacy, vaccine safety, Indonesia, Papua, cross-strain immunity